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Objectives: Effective management of diabetes is the cornerstone for prevention 
of diabetic complications. However, how well the Finnish Current Care guideline 
for diabetes is implemented in practice is unknown. Combining local and nation-
wide patient registers provide a valuable resource for evaluating risks, benefits 
and costs. The purpose of this study was to identify how the Finnish electronic 
patient information systems and national registers can be used to explore the treat-
ment for patients with incident type 2 diabetes. MethOds: Selected primary and 
specialty care organizations representing different geographical areas and patient 
information system providers were invited to participate in the study. Study per-
mits were obtained from several local and nationwide register holders. The study 
protocol was reviewed by the Ethical Review Board of Hospital District of Helsinki 
and Uusimaa. Results: Register linkage is accomplished using unique personal 
identification numbers. We collect nationwide data on prescriptions, hospital and 
primary care, reimbursed dental care, and the causes of death. Cost data are based 
on hospital benchmarking database, sickness allowances and rehabilitations. We 
use local registers as a source of information on diagnoses, medical procedures, 
prescriptions and contact types. High quality laboratory data are also included from 
several local providers. cOnclusiOns: Register linkages enable longitudinal fol-
low-up of patients for research purposes in Finland. In our study a unique combined 
register database of diabetic patient cohort is created that improves the evaluation 
of prognosis and care of diabetic patients. This is a promising and versatile source 
for research in pharmacoepidemiology.
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Objectives: Diabetes mellitus Typ2 (T2DM) is a metabolic disease characterized 
by hyperglycemia with a high risk-potential of microvascular and macrovascular 
complications. In addition to glycemic control important therapy targets are the 
prevention of hypoglycemia and weight gain as well as blood pressure control due 
to national guidelines (German Medical Association 2013). To describe the current 
state of T2DM epidemiology and therapeutic needs in Germany which is mandatory 
when submitting AMNOG dossiers. MethOds: To describe epidemiology of diabetes 
a targeted literature research was conducted in PubMed in 2014 using the search 
terms (epidemiology OR incidence OR prevalence). To identify relevant comorbidity 
information the following terms were used (metabolic syndrome OR glycemic con-
trol OR hypoglycemia OR obesity OR blood pressure) and combined with AND dia-
betes AND Germany. PubMed research was supplemented by additional searches in 
guidelines in German/English. Results: The screening of the epidemiologic results 
identified nine relevant publications: two specified a T2DM-prevalence of 15.3% and 
14.7% (Wittchen et al 2007, Huppertz et al 2009) and two studies estimated a T2DM 
incidence of 15.8 per 1000 patient years (KORA, MONICA). Treatment prevalence 
increased from 5.9% in 1998 to 8.9% in 2007 related to the total population (Hauner 
2013). Arterial hypertension was the most frequent comorbity (83%) of T2DM (Hagen 
et al. 2010). In 2010, a disease management program in North Rhine showed that only 
15% of participants with T2DM achieved a BMI < 25 (Hagen et al. 2010). Long-term 
trials investigating the efficacy of antidiabetics on the prevention of macrovascular 
complications are limited (Drug Commission of German Medical Association 2009; 
Matthaei et al. 2009). cOnclusiOns: While treatment prevalence is increasing and 
glycemic control seems to be sufficiently achieved a substantial unmet medical need 
is identified for antidiabetics with a significant effect on weight reduction and blood 
pressure control in patients with T2DM in Germany.
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Objectives: The objective of this study was to understand the progression over 
time of physiological parameters, including HbA1c, body mass index (BMI), sys-
tolic blood pressure (SBP), total cholesterol, LDL-cholesterol, HDL-cholesterol and 
triglycerides, in type 1 diabetes mellitus (T1DM) patients to inform disease mod-
eling. MethOds: This was a cross-sectional analysis of T1DM patients based on 
the IMS LifeLink Diabetes Cohort in France, which prospectively collects clinical, 
biological and treatment information from general practitioners. Patient age, gen-
der, year of diagnosis, BMI, HbA1c, cardiovascular risk factors, renal function and 
lab test results were collected at baseline and subsequent visits. Data were ana-
lyzed using R Studio. T1DM patients who visited their general physician between 
May 2011 and May 2014 and have received at least one insulin prescription were 
included in the analysis. Results: A cohort of 605 T1DM patients was included 
in this analysis. Forty-three percent of patients were male. Average patient age at 
first visit was 58 years of age. Mean HbA1c was 7.8%, mean SBP was 132 mmHg, 
and mean BMI was 27.6 kg/m2. Linear regression showed that BMI increased by 
0.092 kg/m2 (p< 0.001) for each additional year of age. SBP was projected to increase 
by 0.248 mmHg (p< 0.001) per additional year of age, LDL-cholesterol decreased by 
therapy, with a lower risk of hypoglycemia and without affecting weight versus 
sulfonilurea and metformin combination.
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Objectives: The purpose of this study was to evaluate the effectiveness and safety 
of treatment with recombinant growth hormone (RGH) in children with GH defi-
ciency. MethOds: This was an interventional study with 6 and 12 months follow-
up. Treatment was received by 15 children. The patients were receiving the RGH in 
0.033 mg/kg (0.1 Unit/kg) at the same time each day (9-10 pm) for period of 1 year. 
The effectiveness of treatment was evaluated based on change in growing speed, 
growth SDS and bone age maturation. Results: The mean age of children was 
9.5±3.6 years. In the given sample 6 children had MHPD, other 9 children had IGHD. 
There was a great improvement in absolute growth at 6 and 12 months period of 
treatment (p-0.001; p-0.001). The same was found for growth SDS (p-0.001; p-0.001). 
Effectiveness of RGH therapy on bone age maturation also showed great improve-
ment (p-0.001; p-0.001). The level of IGF-1 was increased (p-0.001; p-0.001); at 12 
months the level of IGF-1 reached to 248.72±70.7 ng/mL and remained consistently 
high. The same improvement was in IGF-pb3 levels (p-0.001; p-0.001). The lipidemic 
analysis showed that the blood cholesterol levels were from 3.21 to 12.39 mmol/L 
(norm 5.68±1.55 mmol/L) and the level of LDL - 1.3 to 10.86 mmol/L (norm 3.83±1.44 
mmol/L). During the treatment period we observed the significant improvement in 
cholesterol levels (p-0.001; p-0.001). High density lipoprotein and triglyceride levels 
did not change significantly (p. 0.05). cOnclusiOns: It can be concluded that the 
treatment with RGH in patient with GH deficiency is beneficial as it normalized the 
levels of cholesterol and LDL. During the treatment there were no any changes in 
indicators of kidney’s function, indicators of liver’s function as well as the indicators 
of carbohydrate metabolism.
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Objectives: To compare the differences of effectiveness, safety and patients’ 
subjective feelings for using different lengths of insulin pen-needle in diabetic 
patients. MethOds: A retrospective analysis of relevant publications that were 
identified via electronic searches of databases using multiple search terms related 
to insulin pen-needle. Results: Totally, 21 literatures were included. Firstly, 
for the effectiveness, 85.71% of the studies suggested that there was no differ-
ence between longer and shorter needle in controlling HbA1c, 14.29% thought 
the shorter needle was better than the longer. No changes were observed with 
respect to fructosamine, glycated albumin and body mass index. Secondly, about 
the safety, all of the studies proved that the shorter needle was better in intra-
muscular injections, adverse device effects, subcutaneous lipodystrophy and barb 
phenomenon. 33.33% reported less hypoglycemic events, bleeding, bruising and 
needle bending with the shorter needle, the others showed no difference. All of 
the studies considered the shorter needle was undifferentiated with the longer in 
the needle break, hyperglycemia and lipohypertrophy. 6.25% have pointed out that 
the shorter needle was better than the longer in leakage, while 81.25% showed no 
difference in the length. Thirdly, in terms of subjective feelings, for convenience 
and acceptance, all studies agreed that shorter needle was superior to the longer. 
For fear and pain, half of studies suggested that shorter needle was superior to the 
longer one; the other half thought that there was no difference. In all the studies, 
69.23% suggested patients prefer the shorter, 23.08% suggested the patients not 
prefer a particular needle length. cOnclusiOns: Overall, the effectiveness of 
insulin pens with longer and shorter needle are comparable in treating diabetes, 
but the shorter needle is little better in parts of the safety indexes. As for patients’ 
subjective feeling, our findings show that patients are generally willing to accept 
shorter needle.
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Objectives: To evaluate resource use and health costs due to the combination 
of metformin and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with dia-
betes and renal failure (RF) in routine clinical practice. MethOds: An observa-
tional, retrospective study was performed. Patients aged ≥ 30 years treated with 
metformin who initiated a second oral antidiabetic treatment in 2008-2009 were 
included. Two groups of patients were analysed: a) metformin + DPP-4 inhibitors 
and b) other oral antidiabetics. The main measures were: compliance, persistence, 
metabolic control (glycosylated haemoglobin < 7%) and complications (hypogly-
cemia, cardiovascular events) and total costs. Patients were followed up for two 
years. Results: We included 395 patients, mean age 70.2 years, 56.5% male: 135 
patients received metformin + DPP-4 inhibitors and 260 patients received met-
formin + other oral diabetics. Patients receiving DPP-4 inhibitors showed better 
compliance (66.0% vs. 60.1%), persistence (57.6% vs. 50.0%) and metabolic control 
(63.9% vs. 57.3%), respectively, compared with those receiving other oral diabetics 
(p < 0.05), and also had a lower rate of hypoglycemia (20.0% vs. 47.7%) and lower 
total costs (€ 2,486 vs. € 3,002), p = 0.001. cOnclusiOns: Despite the limitations 
of the study, patients with renal failure treated with DPP-4 inhibitors had better 
metabolic control, lower rates of hypoglycaemia, and lower health costs for the 
Spanish national health system.
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medications and obstetric medical history. Set-up was non-random, convenience 
sampling with 40 women’s data with mean age 33.7± 3.6, between August 2013 – 
February 2014. Friedmann ANOVA and t-test was applied for analysis with software 
Statistics for Windows. Results: Progresses the gestation period significant reduc-
tion of TSH values was observed in hypothyroid patients (p= 0,0075). Comparing 
successive TSH values of the individual patients showed the same significant dif-
ference. Significant negative correlation was founded between TSH value and thy-
roxin dose in group of hypothyroid patients (r= -0,35; p< 0,05). Premature birth and 
other obstetric complications occured more frequently in the thyreotoxical group, 
especially among older women giving birth. cOnclusiOns: In case of hypothyroid 
pregnant with increasing dose of thyroxin the TSH levels are well balanced, and 
obstetric complications did not occur, while in hyperthyroid patients can be reported 
obstetric complications in addition to proper care.
DiaBetes/enDocrine DisorDers – cost studies
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Objectives: Dapaglifozin is a highly potent, selective and reversible inhibitor of 
sodium-glucose co-transporter 2 (SGLT2) and is approved for the treatment of T2DM 
in adults. Diabetes type 2 is one of the most prevalent chronic diseases that can 
lead to serious complications and disability. The largest costs are those associated 
with hospitalizations due to the complications, the prevention of which requires a 
good glycemic control. The objective of the study is to estimate the budget impact 
of adding dapaglifozin to the therapy of type 2 diabetes in Bulgaria. MethOds: The 
budget impact model was used from the payer perspective for population 7 284 552 
people, and out of them 450000 are type 2 diabetics. The retail pharmacy prices were 
used from the Positive Drug List. Official IMS data for antidiabetic medicines were 
incorporated in the model. Net budget impact is presented as costs per-member 
per-month (PMPM) and costs per-patient per-year (PPPY). Results: An increase in 
the estimated net budget impact from 70 592 € first year to 1 290 716 € for the fifth 
year was observed after adding dapaglifozin to T2DM therapy, with a cumulative 
net budget impact of 3 258 047 € . PMPM and PPPY costs show minimal growth with 
respective cumulative values of 0.06 € and of 65.63 € . The cost for dapaglifozin 
therapy is comparable to that of DPP-4 inhibitors and is lower than the cost of 
treatment with a GLP- 1. cOnclusiOns: The results show that adding dapaglifozin 
to standard therapy will lead to minimal increase in the diabetes type 2 budget in 
Bulgaria. This increase is considered acceptable in terms of better glycemic control 
with safe and effective therapy for diabetes type 2.
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Objectives: Objective of this study is to provide additional evidence for decision 
making to payers assessing health care resource utilization, economic impact, and 
cost-effectiveness of DPP-4 inhibitor alogliptin compared with sitagliptin, saxaglip-
tin and linagliptin, for the treatment of type-2 diabetes mellitus (T2DM). MethOds: 
29 comparable, randomized clinical trials were selected out of a panel of 58 studies. 
6 different clinical endpoints (efficacy and safety) were compared across 5 different 
combinations: DPP-4 Monotherapy, +metformin (MET), +sulfonylurea (SU), +thia-
zolidinedione (TZD), +insulin (INS). For each endpoint and combination, aloglip-
tin clinical endpoints were compared with respective average endpoints of other 
DPP-4s. Differentials were calculated after adjustment for baseline characteristics. 
Each endpoint was associated with the impact on patient outcomes and related 
health care costs (T2DM-related complications, treatment escalation, costs associ-
ated with adverse events: hypoglycemia, cardiovascular mortality, hospitalization 
due to heart failure, lipids profile) obtained from published data. Economic value 
saving of alogliptin was calculated and compared to the other DPP-4s. Results: 
The proportion of patients at target (HbA1c< 7%) as well as the reduced need for 
treatment escalation with alogliptin could generate annual savings for a health care 
system of € 69.62 and € 22.97 per patient-year, respectively. Improved lipids profile 
and proven CV safety of alogliptin can generate savings of € 40.86 and € 21.47 per 
patient-year, respectively. Impact of lower hypoglycemia and increased adherence 
with fixed dose combinations with TZD may generate additional savings (€ 1.53 
and € 1.60/ patient-year, respectively). cOnclusiOns: This study suggests that 
alogliptin could generate significant savings for a Healthcare System, even at price 
parity with other DPP-4s, thanks to its efficacy and safety profile, particularly in the 
widely used DPP-4+MET combination. Total savings of up to € 158 per patient-year 
compare favorably with an overall cost of treatment with a DPP-4i ranging from 
€ 350 to € 481 per patient-year.
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Objectives: To conduct a cost-effectiveness assessment of glucose meters (manually 
coded and autocoded) in diabetes treatment in the Russian Federation. MethOds: 
Clinical effectiveness assessment was based on the results of modeling of the treat-
ment of patients with diabetes that use manually coded and autocoded blood glucose 
meters. Cost analysis included assessment of direct and indirect costs that can be 
0.624 mg/dL for each additional (p= 0.017) year of age and triglycerides increased by 
1.417 mg/dL for each additional (p= 0.041) year of age. Changes in HbA1c, total cho-
lesterol and HDL-cholesterol over time were not significantly correlated with patient 
age or time since diagnosis. Therefore, health economic modelers may assume that 
these parameters remain stable over time. Sensitivity analyses were performed to 
address the potential mislabeling of T2DM as T1DM patients. cOnclusiOns: These 
results provide relevant inputs for the progression of physiological parameters to 
model the economic and clinical impacts of T1DM therapies over time.
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Objectives: To quantify the trend in prevalence and distribution of diabetes mel-
litus (DM) type I (T1DM) and type II (T2DM) in the Netherlands. MethOds: Using 
the General Practitioner Database and the Out-patient Pharmacy Database of the 
PHARMO Database Network, the trend in prevalence of DM and distribution of 
T1DM and T2DM from 2005 to 2012 was assessed. Per year, patients with ≥ 2 anti-
diabetic drug dispensings within 6 months were selected as DM patient. Patient 
numbers were extrapolated to the Netherlands to determine prevalence of DM. 
For all patients, diabetes treatment at September 30 of that year was assessed. For 
patients with a GP recorded diagnosis for T1DM or T2DM, distribution of T1DM/T2DM 
was stratified by treatment. This distribution of DM type by treatment was applied 
to the treatment of patients with no GP recorded DM type to assess the distribution 
of T1DM/T2DM. Results: The prevalence of DM in the Netherlands increased from 
38 per 1000 males and 40 per 1000 females in 2005 to 54 per 1000 males and 52 per 
1000 females in 2012. The distribution of T1DM versus T2DM among patients with 
DM changed from 15% versus 85% in 2005 to 8% versus 92% in 2012. Among patients 
with T1DM mean (±SD) age decreased from 48 (±22) years in 2005 to 44 (±22) years 
in 2012. Among patients with T2DM mean age increased from 63 (±12) years in 2005 
to 67 (±12) years in 2012. cOnclusiOns: This study describes the epidemiology of 
DM in the Netherlands over 2005-2012. Prevalence of DM increased and relatively 
more patients were diagnosed with T2DM. These changes can be explained by the 
ageing Dutch population, better survival, more obesity and early detection of T2DM. 
Furthermore, introduction of the T2DM care program in 2005 probably has led to a 
better registration of T2DM patients.
PDB31
factors associateD with hosPitalization of tyPe 2 DiaBetic Patients 
with hyPoglycemic ePisoDes assisteD at emergency DePartments
Conceição J.1, Laires P.1, Araújo F.2, Dores J.3, Vicente V.4, Silva C.4, Carr R.5, Brodovicz K.6, 
Radican L.7, Nogueira A.M.1
1Merck Sharp & Dohme, Oeiras, Portugal, 2Hospital Beatriz Ângelo, Loures, Portugal, 3Hospital 
de Santo António, Porto, Portugal, 4Eurotrials, Lisbon, Portugal, 5Merck Sharp & Dohme, Ballerup, 
Denmark, 6Merck & Co., North Wales, PA, USA, 7Merck & Co., Inc., Whitehouse Station, NJ, USA
Objectives: HIPOS-ER is an observational, cross-sectional, multicenter study to 
describe the patient population of Type 2 diabetics treated with an anti-hypergly-
cemic agent (AHA) and admitted to the emergency room (ER) with a hypoglycemic 
event. In this analysis we aim to identify factors associated with hospitalization 
following admission in the ER. MethOds: The study enrolled patients from 
7 centers in mainland Portugal for a period of 12 months (Jan 2013 – Jan 2014). 
Sociodemographic and clinical data were collected at the ER and patients who 
required hospital admission were followed up. Multiple logistic regression was 
used to identify factors associated with hospitalization. Results: A total of 238 
patients were enrolled of whom 105 (44%) were hospitalized. These patients were 
older than non-hospitalized (mean: 78 years vs. 75 years; p= 0.020). About half of 
the hospitalized patients were on secretagogue based regimen. Glasgow coma scale 
score was not statistically different between hospitalized and non-hospitalized 
patients (p= 0.270), however hospital admissions showed lower values of the lowest 
recorded plasma/capillary glycemia (mean: 35 mg/dL vs. 41 mg/dL; p= 0.004) and a 
higher prevalence of hypoglycemia complications (26% vs. 9%; p< 0.001). Obesity 
and higher plasma capillary glycaemia level are associated with a lower risk of 
hospitalization (OR= 0.29 and OR= 0.96, respectively; p< 0.010) while treatment with 
secretagogue based regimen, presence of hypoglycemia complications and other 
atherosclerotic disease are associated with a higher risk (OR= 5.71, OR= 3.89 and 
OR= 2.87, respectively; p< 0.010). cOnclusiOns: Almost half of the patients with 
diabetes suffering a hypoglycemic event who required medical assistance at the ER 
were hospitalized. Presence of some factors may increase the risk of these expensive 
cases which are also surrogates for the potential severity of the hypoglycemic epi-
sodes. Identification of these predictors may help assist physicians at the emergency 
room to proactively act upon patients at higher risk of hospitalization and generate 
substantial health and economic gains to the hospitals.
PDB32
the imPact of treatment of thyreoiD Disease in Pregnant women to 
the oUtcome of giving Birth
Ferenczy M.1, Póhr K.1, Lőcsei Z.2, Oláh A.3, Boncz I.4, Karácsony I.1, Salamonné Toldy E.2
1University of Pécs, Szombathely, Hungary, 2Markusovszky University Teaching Hospital, 
Szombathely, Hungary, 3University of Pécs, Pécs, Hungary, 4Faculty of Health Sciences, University 
of Pécs, Pécs, Hungary
Objectives: The most common endocrine clinical symptom is thyroid disease 
which has impact to pregnant women and fetus. Leading international refer-
ences about its treatments are well known, there is no relevant experiences in the 
Hungarian context. Aim of this study is to inspect the thyroid disease and impact 
of its treatment to outcome of pregnancy. MethOds: Survey was carried out at 
Markusovszky Hospital in Vas County, Hungary. Retrospective study made by data 
analysis of pregnant patient with thyroid disease, including hormone parameters, 
